Forest Builds On Viibryd With Levomilnacipran NDA For Its “Middle” Antidepressant
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest hopes the SNRI can follow the enantiomer blockbuster model. The application includes in vitro data showing that levomilnacipran has a greater potency for norepinephrine reuptake inhibition, without directly affecting the uptake of dopamine or other neurotransmitters.
You may also be interested in...
Additional Cariprazine Trial Could Put Forest In A Better Competitive Position
FDA “complete response” letter seeks another trial to better define the most tolerable dose, which could get the atypical antipsychotic to market in a better position than the original dataset.
Additional Cariprazine Trial Could Put Forest In A Better Competitive Position
FDA “complete response” letter seeks another trial to better define the most tolerable dose, which could get the atypical antipsychotic to market in a better position than the original dataset.
Brintellix Label Gives Lundbeck Ground For Tolerability Claims
Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual dysfunction compared to some other drugs.